Navigation Links
Cancer Drug Works Against MS in Early Trial
Date:2/13/2008

maybe T-cells weren't the major players in MS after all, and that perhaps B-cells might play a role. Rituximab, sold under the brand name Rituxan, targets and depletes a type of B-cell known as CD20+.

Hauser's study included 104 people with relapsing-remitting multiple sclerosis. Someone with this type of MS will have disease flare-ups but will also have periods of remission when they don't have symptoms.

The volunteers were randomly assigned to receive either 1,000 milligrams of intravenous rituximab or a placebo. Magnetic resonance imaging (MRI) was conducted at 12, 16, 20 and 24 weeks to assess the number of inflammatory lesions -- a hallmark of MS -- present in the brain.

The number of lesions was reduced in people taking rituximab, and the number of people who had no new lesions was significantly less in those taking rituximab than in those taking a placebo, both during the study and six months later.

The rate of relapse was also significantly reduced for those on rituximab. At the end of the 48-week study period, 20.3 percent of those on rituximab had experienced a relapse versus 40 percent of those on placebo.

What both Hauser and Richert found most exciting was the speed at which rituximab worked and the duration of the benefit, which continued long after the treatment had been administered.

"Beneficial effects were seen by four weeks," said Richert. "Among the reasons why these data are so exciting is that the effects persist after 48 weeks after one course of rituximab."

People taking rituximab did experience more side effects, though most of them were minor. "The big question is whether removal of B-cells will impact the immune system later," said Hauser.

Both Hauser and Richert said this study has also provided new information about the MS disease process, and it will likely open up additional avenues of MS research.

More information

The National
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Drug Works Against MS in Early Trial
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 ... weights, breast milk is more likely than a blood transfusion ... (CMV), a new study finds. The researchers evaluated more ... whom weighed 3.3 pounds or less and many who were ... see whether breast milk or transfusions carried the bigger risk. ...
(Date:9/23/2014)... San Francisco, CA (PRWEB) September 23, 2014 ... search for original 1967 The Doors Eagle Auditorium Seattle concert ... of their album “Break On Through” that year. The Seattle ... According to Hawley, “The Doors would return to Eagles Auditorium ... Doors July poster is not known and comes in three ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has ... electrical services in Vancouver, BC. The company will provide ... a small maintenance project or a large-scale new installation ... meet the needs of the individual commercial client. Pro ... of an affordable price. As a result, businesses of ...
(Date:9/23/2014)... September 23, 2014 The University ... research university located In the Piedmont Triad, announced ... as co-director of the Center for Translational Biomedical ... comes to UNCG after nearly a decade at ... Laboratory, Biological Sciences Division. , “Our goal ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2
... improve the effectiveness of the only tuberculosis vaccine approved ... in a pre-clinical test, report scientists at The University ... Nature Medicine ,s Advance Online Publication March 1. Their ... funded by the National Institutes of Health (NIH). ...
... Medical Event Available from the Convenience of a Computer, www.CardioCareLive.com ... from 9:30 AM to 8:00 PM Eastern.,Patch Adams, MD, the real ... speak. To register now for free, visit cardioCareLive.com. , ... ...
... American Public Health Association,s (APHA) new Fluoridation Position ... support nor evaluate fluoridation,s safety and/or effectiveness as ... Fluoridation, Inc. APHA asserts, "All of these reviews ... safe and effective." Here,s the truth about APHA,s ...
... drug-eluting stentNATICK, Mass., March 3 Boston Scientific ... the launch of its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary ... approved on January 28 by the Ministry of ... yesterday by the National Health Insurance System.TAXUS Liberte ...
... patients, the soles of their feet and the palms of ... because of some types of chemotherapy. Patients, family members also ... , Both share a need for quick answers or ... diagnosis, treatments, or unexpected symptoms. , A new section ...
... to Defend His TitleNORTHRIDGE, Calif., March 3 There ... names, two decks of shuffled playing cards, or a ... minutes. Chester Santos, the 2008 USA National Memory Champion, ... when he defends his title at the USA National ...
Cached Medicine News:Health News:TB breakthrough could lead to stronger vaccine 2Health News:TB breakthrough could lead to stronger vaccine 3Health News:CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today 2Health News:APHA Misleads Americans About Fluoridation 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 3Health News:Walther Cancer Foundation grant funds new IU Simon Cancer Center Web site section 2Health News:The Making of a Memory Champion 2Health News:The Making of a Memory Champion 3
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)...  SiteOne Therapeutics Inc. today announced the completion of ... Capital Management and Biobrit LLC, with additional investors Mission ... million financing positions SiteOne to advance its oral Na ... develop its technology platform for long-acting local analgesics, pain ... with the financing, Lowell Sears (Sears Capital ...
(Date:9/23/2014)... Sept. 23, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Letter (NOL) from Health Canada to begin clinical ... its lead product candidate KP201 (benzhydrocodone hydrochloride and ... for acute moderate to moderately severe pain. The ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... PXS) today announced significant results of pooled data from ... of Bronchitol (inhaled mannitol) in people with cystic fibrosis. ... the first time at the North American Cystic Fibrosis ... results from the second trial (CF302) have been released ...
... Oct. 22 INVO Bioscience, Inc. (OTC Bulltin Board: ... for patients diagnosed with infertility, today announced that Dr. ... (CECOFLES LTDA) will present the results of the first ... INVO Bioscience,s INVOcell technology at the 66th Annual Meeting ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 2INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 3
Transcranial vascular DWL doppler....
... is an automated system capable of handling ... definition of many of the tests allows ... your patients' and staffs' needs. Any tests ... automated tests can easily be handled using ...
The CD Horizon M10 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
... Neurocare - continues the revolutionary ... Exceptional convenience and speed. Superior Doppler ... delivers features you won't find anywhere ... cuff attachment and testing. Up to ...
Medicine Products: